Contemporary analysis of the functional responses of G-protein-coupled receptors (GPCRs) usually addresses drug-receptor interactions from the perspective of the average behavior of the receptor population. This behavior is characterized in terms of observed affinity and efficacy. Efficacy is a measure of how well a drug activates the receptor population and observed affinity a measure of how potently a drug occupies the receptor population. The latter is quantified in terms of the dissociation constant of the ligand-receptor complex. At a deeper level of analysis, drug-receptor interactions are described in terms of ligand affinity constants for active and inactive receptor states. Unlike observed affinity and efficacy, estimates of receptor state affinity constants are unperturbed by G proteins, guanine nucleotides, or other signaling proteins that interact with the receptor. Recent advances in the analysis of the functional responses of GPCRs have enabled the estimation of receptor state affinity constants. These constants provide a more fundamental measure of drug-receptor interactions and are useful in analyzing structure-activity relationships and in quantifying allosterism, biased signaling, and receptorsubtype selectivity.
A single-receptor view of drug action Drug-receptor interactions are often illuminated when viewed from the perspective of single receptors. Single receptors isomerize between active and inactive states depending on the nature of the ligand bound to them ( Figure 1A ) [1] [2] [3] [4] . When unbound, most receptors remain inactive except for occasional fleeting activations (constitutive activity). These activations have greater frequency and longer duration when the receptor is bound with an agonist. Agonists bind to both receptor states, but they extend the mean duration of the active state because of their higher affinity for it. For the purpose of measuring drug action, receptor states are defined by their activity and affinity for specific ligands [5, 6] . Certainly there are numerous vibrating conformations of each state as well as additional evanescent transition states.
In contemporary analysis of GPCRs, the frame of reference is usually the receptor population [7] [8] [9] [10] . For a population of eight receptors, activation in the presence of agonist approaches a mean level with considerable relative variation ( Figure 1B ). As the size of the receptor population increases to 200, activation is nearly constant in time after reaching equilibrium ( Figure 1C ). Unlike the bound or unbound condition of a single receptor, occupancy of a population of receptors is represented by a graded variable ranging from zero to one ( Figure 1D ). The observed dissociation constant (K D ) designates the position of the ligandoccupancy function on the log ligand-concentration scale. For a specific population of receptors, both half-maximal occupancy and receptor activation occur at an agonist concentration equivalent to the value of K D ( Figure 1D ). The ability of a ligand to activate the receptor population is represented by the parameter efficacy, which is defined as the fraction of the occupied receptor population in the active state. For example, if 30% of the receptor population is occupied and one-third of these ligand-receptor complexes are in the active state, the value of efficacy is 0.33.
Although the observed affinity constant (K obs , 1/K D ) determines receptor occupancy, no stable receptor structure having an agonist affinity constant of K obs exists. Rather, there are at least two structures (active and inactive states) characterized by affinity constants of K act and K inact , respectively ( Figure 1A ,E). The value of K obs represents a weighted average of the values for K act and K inact (Table 1) . Hence, K obs might better be termed occupancy constant.
By contrast, the relationship between the efficacy and the activation state of single receptors is simple. If the time that a single ligand-receptor complex spends in the active state is divided by the total time that the receptor is occupied, the result is a unitless fraction between zero and one that represents the probability that the ligandreceptor complex is in the active state. This probability is equivalent to the population concept of efficacy defined above.
Recently, methods for estimating receptor state parameters from functional assays on GPCRs have been described. In this review, I explain some intuitive relationships between receptor state and population parameters and briefly review the experimental paradigms from which state parameters can be estimated.
A model for GPCR activation
The simulation depicted in Figure 1 adequately portrays activation of the soluble ligand-binding domain of the dimeric metabotropic glutamate receptor 4 [4]. An analogous model with two cooperatively linked orthosteric sites would resemble the behavior of many ligand-gated ion channels of the Cys-loop and glutamate families [11] . However, how does the simulation relate to a receptor coupled to G proteins?
The interactions among orthosteric ligand (D), receptor states (R and R*), G protein, and guanine nucleotide have been described using the quaternary complex model [12, 13] . Its most recent description includes GTPase activity, the guanine nucleotides GTP and GDP, and three states of G protein [14] . The latter correspond to the crystal structures of GDP-bound holoprotein (inactive, G) [15] , GTP-bound G a subunit (active, Ga**) [16] , and agonistoccupied receptor-G protein complex (exchange, G*) [3] . The exchange state exhibits high affinity for the active state of the receptor (R*) and low affinity for GTP and GDP. For various conditions, simulations with this model identify the form of the agonist-receptor complex that initiates signaling. This component is the active state of the agonist-receptor complex bound with the exchange state of the GDP-occupied G protein (quaternary complex, DR*G*GDP) (Figure 2A ). In the presence of GTP, the quaternary complex rapidly exchanges GTP for GDP, causing the resulting GTP-bound G a and loosely associated G bg subunits to dissociate from the receptor. Thus, the quaternary complex is the immediate precursor of activated G proteins (GTP-G a and G bg ) and represents the biophysical correlate of receptor activation (i.e., stimulus function of Stephenson [9] and Furchgott [17] ). It follows that the concentration of agonist generating half-maximal formation of DR*G*GDP is equivalent to the agonist's K D value (1/K obs ) and that the fraction of the agonist-occupied receptor population in the DR*G*GDP complex is proportional to efficacy (e) ( Figure 2B ). The value of these population parameters can change depending on the G protein, its relative abundance, and the concentrations of guanine nucleotides. By contrast, estimates of ligand-affinity constants for a receptor state involved in signaling through a specific G protein are unaffected by variation in the concentrations of G protein and guanine nucleotide [13, 14, 18] .
Relationship between population parameters and receptor state affinity constants When a ligand induces a protein to assume a different conformation, some of the intrinsic binding energy associated with the induced state is used to cause the conformational Table 1 ) as described previously [21] . change [19] . Hence, the observed affinity constant of a ligand for the receptor population can be much less than its affinity for the state that it induces. The amount of agonist-induced activation of a GPCR can be expressed as a ratio (activation ratio, R act ) equivalent to the fractional amount of ligandreceptor complexes in the active state (efficacy, e) divided by the fractional amount of unoccupied receptors in the active state (constitutive activity, e 0 ) (R act = e/e 0 ). If the observed affinity constant of the agonist-receptor complex is multiplied by the activation ratio, the result is the value of the active state affinity constant (Figure 3 ) [20] :
For example, consider a highly efficacious agonist with an observed affinity constant ( , log K act , 8.70 ). An analogous calculation can be used for estimation of K inact [18] .
This concept can be restated as a corollary for ligandinduced conformational changes [21] . That is, the affinity constant of a ligand for a particular receptor state (K j ) is equivalent to the product of the observed affinity (K obs ) and the fraction of the population of ligand-receptor complexes in the state (e j ) divided by the fraction of the unoccupied receptor population in the same state (e 0-j ):
[2]
Estimates of e and e 0 are unneeded for these calculations. When functional data are analyzed with the operational model, t values can be estimated (t and t 0 ,) that are proportional to e and e 0 , respectively [20] . Hence, one can estimate the activation ratio (R act ) as t/t 0 and therefore:
A more robust approach is to analyze the appropriate functional data using nonlinear regression analysis with a version of the operational model in which K act is substituted for tK obs /t 0 or the total stimulus function is expressed in terms of receptor state parameters instead of population parameters [13, 20] . Additional relationships between receptor state and population parameters are given by Ehlert and Griffin [13] and in Table 1 .
When applied to the phosphoinositide response of the human M 3 muscarinic receptor, this analysis yielded estimates of 4 3 10 7 and 10 4 M À1 for the K act and K inact values of the efficacious agonist oxotremorine-M [20] . The analogous estimates for carbachol were 1.6 3 10 7 M À1 and 5.5 3 10 3 M
À1
. Because acetylcholine has tenfold-greater potency than carbachol for eliciting M 3 responses [22] , the results suggest a K act value of approximately 10 8 M À1 for acetylcholine. Nearly the same K act value was estimated for acetylcholine at the muscle-type nicotinic receptor (5 3 10 7 M
) [1] using single-channel analysis, suggesting that optimal binding pockets have evolved for acetylcholine on muscarinic and nicotinic receptors [23] . An affinity constant of 10 8 M À1 represents a binding energy of about 11 kcal mol À1 or 1.1 kcal mol À1 per non-hydrogen atom of acetylcholine, which is similar to that of the biotinstreptavidin interaction (1.2 kcal mol À1 per non-hydrogen atom of biotin).
The K obs value of epinephrine for the b 2 adrenoceptor (binding assay estimate) increases 1000-fold in the presence of G s or an antibody stabilizing the active receptor state [24] , indicating the more than 1000-fold selectivity of epinephrine for the active state (i.e.,
A relative estimate of the active state affinity constant An easy state parameter to estimate in functional studies is a relative value of the active state affinity constant. For the case of two full agonists A and B, relative affinity for the active state (K act-B /K act-A ) is equivalent to the corresponding ratio of potencies (EC 50-A /EC 50-B ) [25, 26] . For full and partial agonists, the ratio of equiactive agonist concentrations approaches a constant limiting value at low concentrations of the agonists (EAMR) [26] . EAMR was later termed RA i and defined as the product of affinity and efficacy of a given agonist (eK obs ) expressed relative to that of a standard agonist (e 0 K obs 0 ) [27, 28] :
As shown above, the efficacy terms can be replaced with the appropriate t values from the operational model. The RA i value, raised to the exponent m (transducer slope factor), was also shown to be equivalent to the ratio of initial slopes of two concentration-response curves [27] . Subsequently, the RA i value was shown to be equivalent to the active state affinity constant of an agonist (K act ), expressed relative to that of a standard agonist (K act 0 ) [25] , which is also indicated above and can be easily derived from Equation 3. Kenakin and coworkers [29] [30] [31] Log R act =3.7 Log R act =3.7
Log acƟvaƟon raƟo (log R act ) 
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used the term transducer ratio for t/K D and the variable Dt/K D for RA i .
The RA i value can be estimated from two or more agonist concentration-response curves even if there is insufficient information to estimate the observed affinity (K obs ), the relative efficacy (e/e 0 ), the t value, or even the product tK obs for each agonist. It is, nonetheless, always possible to estimate RA i . Figure 4 shows an example of a simulation that illustrates this point for two partial agonists. Panel A shows the concentration-response curves of two agonists. Because both drugs are partial agonists, it is impossible to estimate any of the individual parameters of the operational model with any degree of accuracy, including the maximal response of the system, the observed affinity (K obs ), the t value, and the product tK obs of either agonist. Nonetheless, the log RA i value AE SEM of agonist 2 relative to agonist 1 can be estimated (À0.96 AE 0.062) using regression methods described previously [27, 32] . This value is nearly the same as that used in the simulation (log RA i , À1.0).
Panels B-E show the results of the analysis after the responses measured at the higher concentrations of agonist are progressively removed, one at a time, from each successive panel in alphabetical order. Remarkably, it remains possible to estimate the RA i value with reasonable accuracy after the four largest response values are removed from each curve (panel E), although it is impossible to estimate the EC 50 and E max values of the curves or any of the primary parameters of the operational model except the composite parameter tK obs /t 0 K obs 0 (RA i ). This result illustrates the fundamental nature of the active state affinity constant.
Analysis of allosterism yields all of the receptor state parameters Allosterism is defined by a subcommittee of the International Union of Basic and Clinical Pharmacology as a modification of the properties of a ligand caused by the binding of a second ligand at a distinct site [33] . This mechanism can account for reciprocal modulation in ligand binding. It can also account for effects on ligand efficacy that are unrelated to a change in the conformation of the receptor. For example, an allosteric inhibitor could bind to the open state of a ligand-gated ion channel and plug the channel, causing an increase in orthosteric agonist affinity and an inhibition of channel function (open channel block). Similarly, an allosteric inhibitor could bind to the active state of a GPCR and competitively displace the G protein resulting in increased orthosteric binding affinity and decreased efficacy.
A more restrictive way of defining allosterism involves determining whether the allosteric effect is indistinguishable from a change in the isomerization constant of the unoccupied receptor [5] . The isomerization constant (K q ) defines the spontaneous equilibrium between the unoccupied active (R*) and inactive (R) states of the receptor (K q = R*/R). An allosteric ligand that acts in this manner has the effect of altering the isomerization constant by the factor K f /K e , in which K f and K e denote the affinity constants of the allosteric ligand for active and inactive receptor states ( Figure 5A ) [5, 34] . Here, the effects of such a ligand are termed purely allosteric. Some candidate purely allosteric agonists include the M 1 -and M 2 -selective ligands described by Christopoulos and coworkers [35, 36] . 
TRENDS in Pharmacological Sciences
Key: Figure 4 . Estimation of the log RA i value of partial agonist B, expressed relative to that of partial agonist A. The concentration-response curves of two partial agonists (A and B) having different log observed affinity constants (K A , 5.0, and K B , 4.5) and log t values (t A , 0.3, and t B , 0.03) were simulated using the operational model with values of 1.0 for the transducer slope factor (m) and maximum response of the system (M sys ) and a 10% random error. The mean values AE SEM of four simulated replicates are shown. The simulated data were analyzed by global nonlinear regression analysis using a form of the operational model described by Ehlert [32] having parameters M sys , m, log K A , log R (log t A K A ), log K B , and log RA i (t B K B /t A K A ). The theoretical curves represent the least-squares fit to the data. In each case, an accurate value of log RA i was estimated as shown in the plot. By contrast, it was impossible to obtain accurate estimates of the other parameters. The plots differ regarding the number of data points used in the regression analysis [nine to five for (A-E), respectively]. For example, consider a receptor having an isomerization constant of 10 À4 ( Figure 5B ). In the absence of ligands, the fraction of the receptor population in the active state (constitutive activity, e 0 ) would be approximately 10 Table 1 ). In the presence of a purely allosteric modulator, with threefold selectivity for the active receptor state (K f /K e = 3), the receptor would behave as if its isomerization constant has increased threefold. In most instances, it would be difficult to measure the associated increase in constitutive activity (threefold), but not the corresponding increase in the affinity (1.5 times) and efficacy (twofold) of an efficacious agonist with 3000-fold selectivity for the active state ( Figure 5C ). The combined effects would be obvious in a sensitive output assay for GPCRs ( Figure 5D ).
If a purely allosteric agonist is available for a GPCR or, alternatively, if the GPCR exhibits constitutive activity and the action of the modulator is purely allosteric, it is possible to analyze the allosteric interaction and estimate the receptor state affinity constants of the orthosteric (K act , K inact ) and allosteric (K f , K e ) ligands, the observed isomerization constant of the unoccupied receptor (K q-obs ), the observed sensitivity constant of the transducer function of the operational model (K E-obs ), and all of the population parameters for the allosteric interaction [13] . Almost any output assay for GPCRs can be used in the analysis. The essential requirements of the protocol include measuring the independent effects of the allosteric and orthosteric ligands under control conditions and their interaction under conditions of partial receptor inactivation or reduced receptor expression. The various state parameters that can be obtained from this analysis are described by Ehlert and Griffin [13] .
Having estimated the observed isomerization (K q-obs ) and sensitivity (K E-obs ) constants (see Table 1 for definitions) of a particular output response, an investigator could estimate the receptor state affinity constants of various additional orthosteric and allosteric agonists (test ligands) through analysis of their individual concentration-response curves. In this analysis, global nonlinear regression analysis is done on two sets of data: (i) the allosteric interaction described in the prior paragraph for a single full agonist; and (ii) a series of concentration-response curves for test agonists [13] . For any full agonist in this latter group, an additional concentration-response curve measured under the condition of reduced receptor The influence of allosteric modulation on the output response of a G-protein-coupled receptor (GPCR). The concentration-response curves were generated using the operational model with a sensitivity constant (K E ) of 0.01 and a transducer slope factor (m) of 2.0. The stimulus inputs to the model were the simulated activation curves in (C).
expression or partial receptor inactivation is needed for estimation of K inact .
One of the easiest parameters to extract from functional studies on allosterism is the affinity constant of an allosteric ligand for the active state of a GPCR. It is always possible to estimate the product of maximal changes in the allosteric modulatory effects on the affinity (DK obsÀmax , a) and efficacy (De max , b 1 ) of an agonist in functional assays [37, 38] . This cooperative effect was initially designated '1/B' but has been renamed using the variable g 1 (g 2 denotes the maximal scalar effect of the orthosteric ligand on the affinity and efficacy of the allosteric ligand) [13] .
The simulation in Figure 6 illustrates how these parameters are related to allosteric modulation of receptor activation (panel A) and the resulting output response (panel B). Figure 6C shows the allosteric effect, expressed as the product of the observed changes in the affinity and efficacy of the orthosteric ligand (DK obs De), plotted against the concentration of modulator. The maximal value of DK obs De is equivalent to g 1 . Figure 6D illustrates that receptor occupancy by the allosteric ligand is equivalent to the normalized DK obs De value (DK obs De À 1 divided by the maximal value of DK obs De À 1) [13] . Lazareno and Birdsall [39] have described the analogous relationship for occupancy and allosteric modulation in ligand binding affinity.
Unlike the reciprocal allosteric effects that orthosteric and allosteric ligands have on their respective binding affinities (a), g 1 is determined only by the allosteric ligand. It is equivalent to the ratio of the efficacy of the allosteric ligand (e A ) divided by the efficacy of the unoccupied receptor (e 0 ) [13] . It can also be defined using the corresponding t values from the operational model (i.e., g 1 = t A /t 0 ). Thus, g 1 is analogous to the activation ratio (R act ) mentioned above in connection with orthosteric ligands. It can be shown that the product of the observed affinity of the allosteric ligand (K obs-A ) and g 1 is equivalent to the affinity constant of the allosteric ligand for the active state [13] :
Both g 1 and K obs can be estimated from data like those shown in Figure 6B using global nonlinear regression analysis with the appropriate regression equation [13, 40] . Alternatively, the regression equation can be written in terms of state parameters and estimates of K f can be obtained directly without using Equation 5 [13] .
Implications for drug discovery With estimates of an agonist's receptor state affinity constants in hand, an investigator has a means of comparing the activity of an agonist at different receptor subtypes and determining its ability to persuade a given receptor to signal through different pathways. Different receptor coupling proteins provide a window for estimating agonist affinity for effector-selective states of the receptor [20] . These estimates depend only on the active and inactive states of the receptor involved in triggering the response. This brief review has focused mainly on G protein signaling, but the same considerations apply to arrestin signaling [41, 42] . Additional complications arise with arrestin signaling, however, regarding the liganddependent rate of receptor phosphorylation by GRK and potential receptor dephosphorylation at the plasma membrane before recruitment of arrestin [43] [44] [45] . The RA i estimate has been used as a means of detecting agonist bias through different signaling pathways [25, 28, 32, 46] . The rationale is based on the assumption that the active state is the first cause of downstream responses and that different relative estimates of K act (RA i ) imply different active states that mediate the different responses. Although the difference between the RA i values (Dlog RA i ) of an agonist for eliciting two different responses is useful for detecting bias, neither the RA i value itself nor the component of the RA i value reflecting the eK obs value (e.g., tK obs ) of a given agonist is a measure of the ligand's ability to transduce a signal. Rather, eK obs is equivalent to the product of the active state affinity constant and constitutive activity (eK obs = K act e 0 ) [20] . Similarly, tK obs is equivalent to K act t 0 (see Equation 3 ).
The population definition of efficacy gives rise to somewhat unexpected behavior at the very low end of the scale. For example, the efficacy of a neutral antagonist is equivalent to constitutive activity (e 0 ) and that of an inverse agonist is between e 0 and zero [20, 21] . The efficacies of neutral antagonists and inverse agonists, or their corresponding t values, can be estimated in functional assays that report constitutive activity [20] or through the allosteric approach reviewed in the prior section. It follows that RA i values can be estimated for both inverse agonists and neutral antagonists and that the RA i value of an inverse agonist can be larger than that of an agonist. Nonetheless, the Dlog RA i value of an inverse agonist accurately reflects the log difference in its affinity constants for the active receptor state, relative to that of the standard agonist, when estimated for different output assays.
The activation ratio (R act or g 1 ) is a useful parameter for estimating receptor signaling through a particular pathway, particularly if the response is a natural one of clinical importance. Incidentally, this parameter can also be calculated as K act /K obs (see Equation 1) . Changes in the concentration of GTP or G protein can influence constitutive receptor activity more so than agonist efficacy [20] . Thus, the R act value (t/t 0 ) of an agonist for a response can vary depending on the expression level of signaling components.
If the goal is drug screening using native and nonnative cellular assays, the selectivity of a drug for the active receptor state (i.e., K act /K inact ) is a better estimate of pathway activation. This parameter is invariant for a particular signaling pathway and has previously been suggested as a measure of efficacy at the receptor state level of analysis [6] . There is no problem with having two different definitions of ligand efficacy, based on single-receptor or population analysis, provided that the level of analysis is clearly specified [21] . Here, I refer to the ratio K act /K inact as the induction ratio (R induct ). An agonist could have similar K act /K inact values for two different pathways but exhibit a bias for one pathway because of its higher affinity for both the active and inactive states of its preferred pathway. Thus, knowledge of the individual estimates of K act and K inact is useful in understanding biased signaling and an absolute estimate of K act is better than a relative one (RA i ).
If the agonist first binds to the same inactive state of the receptor when initiating signaling through different pathways, the corresponding differences in log R induct (Dlog R induct ) would be equivalent to Dlog RA i . Although it might seem unlikely that K inact would vary for the same ligand-receptor complex when signaling through different pathways, it is possible that it does and that changes in log K inact underlie a component of agonist efficacy in some instances. Differences in a ligand's K inact value could give rise to biased antagonism. The binding pocket and cytosolic ends of helix 5 and 6 of the b 2 adrenoceptor are thought to undergo dynamic changes in the inactive state [47] , which could provide the basis for differences in K inact .
While estimates of K inact require more data than RA i , future studies employing the methods described above in the section on allosterism could yield a database of observed receptor isomerization (K q-obs ) and sensitivity (K E-obs ) constants for various signaling pathways in defined cells and tissues used in drug screening. These values would enable investigators to estimate K act and K inact from agonist concentration-response data as described above.
Concluding remarks
The past few years have witnessed a surge in our understanding of receptor structure, which will surely continue as more active and inactive receptor structures are solved. The population analysis that has driven pharmacology over the past few decades is insufficient for advancing analysis of receptor function in the present era. A scientist interested in designing a more potent analog of a drug, for example, might dock the parent drug onto the active and inactive receptor structures in silico and determine how an added substituent interacts with a specific amino acid side chain in both structures. Estimating receptor state affinity constants in functional assays provides a means of verifying conclusions drawn from such in silico investigations. By analogy, receptor state analysis improves structureactivity relationship studies, which currently relate drug structure to potency (EC 50 ) or observed binding affinity (K i value). Knowing how modification of a ligand structure alters its affinity for active and inactive receptor structures provides more useful information in these analyses, particularly regarding pathway induction (K act /K inact ) and bias. Hence, functional analysis of receptor states represents an adjunct to structural analysis.
Receptor states are the first cause of pharmacological effects and hence their ligand-affinity constants are the ultimate measures of drug action because they provide an estimate of how well a drug turns on a receptor.
